Although direct clinical evidence of systemic NAD(P) depletion during GLP-1RA therapy is lacking, experimental and observational studies suggest that NAD turnover and micronutrient status can be altered in obesity and inflammatory states [83, 85], supporting the biological plausibility of substrate-sensitive vulnerability
Be cautious of exaggerated claimsno glutathione supplement is currently approved by the MHRA for treating fatty liver disease, and any product making specific disease treatment claims may be in breach of UK advertising regulations
Facts & Comparisons eAnswers
What Are GLP-1 Receptor Agonists and Peptide Treatments
Novo Nordisk and Eli Lilly turn their attention to GLP-1 effects on alcohol As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two pharma giants that are responsible for the development of the current crop of blockbuster GLP-1 drugs: Novo Nordisk and Eli Lilly
Patients with high Kla scores show poorer responses to immune checkpoint blockade (ICB) therapy with higher disease progression rates, as ICB efficacy correlates closely with TME immune cell infiltration
